肛肠医院中山华都医院(中山混合痔治疗混合痔医院) (今日更新中)

The CDC is considering changing its quarantine guidelines for those who have been in close contact with someone who is infected with the coronavirus.Currently, those who have been in close contact with someone infected with the virus would be advised to quarantine for 14 days. Possible new guidance would shorten the quarantine period to 10 days. At the end of the 10-day period, a test would be need to end quarantine.In an interview with CNN’s Wolf Blitzer, Adm. Brett Giroir, the assistant secretary for health at Health and Human Services, explains why a 10-day quarantine might be more effective at getting more compliance with the guidance."People are much more likely to listen to a 10-day quarantine than they are a 14-day quarantine,” Giroir said. “If we can shorten it safely with most risk because we have a quarantine plus a test, we have a lot of tests available now, that might improve our public health responses.”Giroir stressed that final guidelines have not been approved, and the current guidance still calls for a 14-day quarantine.“It's not an announcement that is happening but we are reviewing it and the CDC team is modeling it and looking at data every day,” Giroir said.“And it may change or it may not. Just depends on where the data and the evidence wind up." According to the CDC, a person can become infected with the virus up to 14 days following exposure. But researchers say most illnesses begin five to seven days after COVID-19 exposure.A close contact is considered someone who is within 6 feet of someone with the virus for a period of 15 minutes or more over the course of a day. 1626

The cast and crew of "Parks and Rec" are reuniting for a political cause.Amy Poehler and other stars of the show will participate in a virtual town hall on Thursday to raise money for the Democratic Party of Wisconsin.Series creator Michael Schur is also slated to make an appearance.The event is scheduled to begin at 8 p.m. CT, and anyone who donates money will be able to participate in a Q&A at 8:30 p.m., the group stated on its website.In April, the cast came together to raise money for Feeding America. 522

The current spike in COVID-19 cases is stressing the testing system across the country.As the virus spreads at unprecedented rates, more Americans are seeking COVID-19 tests. But in recent days, companies that make the tests and the supplies needed for them are struggling to keep up with demand."Those companies were operating on an allocation basis, and that just means that basically everything they make is going out the door," said Kelly Wroblewski, the Director of Infectious Disease Programs at the Association of Public Health Laboratories. "There is no reserve, so there's an increased demand in a lab for testing. There's no more reagent to be had, so to meet that demand, that lab has to use a different manufacturer's test."Wroblewski adds that along with issues in getting supplies, officials are also short on human resources — there is only so much lab capacity and only so many trained people to conduct the tests.The American Clinical Laboratory Association says the surge in demand for testing means some labs could reach or exceed their current testing capacities soon — meaning it could take longer for patients to get PCR test results back.Wroblewski says that it can take currently take anywhere from 24 hours to a week to get PCR test results back.With antigen tests, patients can get results back in less than 30 minutes. There is currently enough of a supply for antigen tests, but not all facilities offer them.Both lab groups stress that COVID-19 testing is important, but patients should be strategic."There's been a lot of emphasis put on testing, but testing is only one piece of the puzzle," Wroblewski said. "It gives you some information, and if you're not going to do anything with that information — whether it be targeted closures. whether it be staying home and isolating — we're not going to stop the spread of disease."As far as getting more tests, it's going to take a while. Wroblewski says it could take up to six months or more to increase production capacity significantly. Labs don't expect to see a ramp-up in supplies until early 2021. 2090

The family of Pfc. Vanessa Guillen, an Army soldier who was allegedly killed by a fellow soldier and his girlfriend, met with President Donald Trump on Thursday.Guillen's family began the day with a morning march on the National Mall in support of a military-focus sexual harassment bill bearing her name. The family and their attorney later met with the President at the White House.The event was closed to the press."It hit me very hard," Trump said later Tuesday about meeting with Guillen's family, according to CBS News. "We didn't want this to be swept under the rug."Guillen was last seen on April 22 at Fort Hood, Texas, where she had been stationed. On June 30, Guillen's dismembered remains were found on the banks of a nearby river.Hours later, a suspect in the case, Spc. Aaron Robinson died by suicide during a standoff with police. Robinson's girlfriend, Cecily Ann Aguilar, was later charged with assisting in hiding Guillen's body. Aguilar has pleaded not guilty.Guillen's family maintains that she had been sexually harassed by Robinson and others prior to her disappearance. They claim she did not report the abuse to her superior officers because she feared retribution.While an investigation into sexual harassment against Guillen remains open, the Army has not yet confirmed the family's claims. According to ABC News, the Army has confirmed that Guillen may have been harassed, but it was not of a sexual nature.The bill for which Guillen's family was marching, the #IAmVanessaGuillen Bill, would allow military members to file harassment claims with third-party agencies instead of within their chain of command."We will not accept anything less than justice for Vanessa," Attorney Natalie Khawam said, according to KPRC-TV in Houston. "When someone volunteers to serve our country, they deserve to be treated with dignity and respect by their fellow service members. This bill will help us provide the protection and respect to others that was denied to Vanessa." 1995

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

来源：资阳报